Early metabolic response assessment to neoadjuvant endocrine treatment in ER+, HER2-breast cancer: comparison to the morphological and pathological response

被引：0
|
作者：
Boughdad, Sarah [1 ]
Champion, Laurence [1 ]
Becette, Veronique [2 ]
Cherel, Pascal [2 ]
Mouret-Fourme, Emmanuelle [2 ]
Edeline, Veronique [1 ]
Lemonnier, Jerome [3 ]
Lerebours, Florence [2 ]
Alberini, Jean-Louis [1 ]
机构：
[1] Ctr Rene Huguenin, Inst Curie, Nucl Med, St Cloud, France
[2] Ctr Rene Huguenin, Inst Curie, St Cloud, France
[3] Unicancer, Paris, France
来源：
JOURNAL OF NUCLEAR MEDICINE | 2015年 / 56卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
1311
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Defining the transcriptional and biological response to CDK4/6 inhibition in relation to ER+/HER2-breast cancer
    Knudsen, Erik S.
    Witkiewicz, Agnieszka K.
    ONCOTARGET, 2016, 7 (43) : 69111 - 69123
  • [22] Nodal pCR and overall survival following neoadjuvant chemotherapy for node positive ER+/Her2-breast cancer
    Moldoveanu, Dan
    Hoskin, Tanya L.
    Day, Courtney N.
    Schulze, Amy K.
    Goetz, Matthew P.
    Boughey, Judy C.
    BREAST CANCER RESEARCH AND TREATMENT, 2024, 203 (03) : 419 - 428
  • [23] Tumor-infiltrating lymphocytes (TILs) in ER+/HER2-breast cancer
    Criscitiello, C.
    Vingiani, A.
    Maisonneuve, P.
    Viale, G.
    Vialel, G.
    Curigliano, G.
    BREAST CANCER RESEARCH AND TREATMENT, 2020, 183 (02) : 347 - 354
  • [24] Predictive score for response to neoadjuvant chemotherapy in early-stage HR + /HER2-breast cancer
    Coelho, Joao Queiros
    Lau, Beatriz
    Pichel, Rita
    Guerra, Laura
    Miranda, Hugo
    Romao, Raquel
    Sousa, Maria Joao
    Goncalves, Fernando
    Simoes, Joana
    Azevedo, Sergio Xavier
    Araujo, Antonio
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2025,
  • [25] Role of androgen receptor expression in early stage ER+/PgR-/HER2-breast cancer
    Tagliaferri, Barbara
    Quaquarini, Erica
    Palumbo, Raffaella
    Balletti, Emanuela
    Presti, Daniele
    Malovini, Alberto
    Agozzino, Manuela
    Teragni, Cristina Maria
    Terzoni, Andrea
    Bernardo, Antonio
    Villani, Laura
    Sottotetti, Federico
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2020, 12
  • [26] Neoadjuvant chemotherapy in ER+ HER2− breast cancer: response prediction based on immunohistochemical and molecular characteristics
    E. H. Lips
    L. Mulder
    J. J. de Ronde
    I. A. M. Mandjes
    A. Vincent
    M. T. F. D. Vrancken Peeters
    P. M. Nederlof
    J. Wesseling
    S. Rodenhuis
    Breast Cancer Research and Treatment, 2012, 131 : 827 - 836
  • [27] Treatment of ER+/HER2+breast cancer
    Johnston, Stephen
    CANCER RESEARCH, 2023, 83 (05)
  • [28] Real World Data on Neoadjuvant Endocrine Treatment and Ki67 Assessment in ER+/HER2-Breast Cancer. Results from a Single-Institution Prospective Cohort Study
    Marti, Covadonga
    Frias, Laura
    Loayza, Adolfo
    Moreno, Elisa
    Melendez, Marcos
    Sanchez-Mendez, Jose Ignacio
    CANCER RESEARCH, 2023, 83 (05)
  • [29] ASO Visual Abstract: Axillary Response to Neoadjuvant Therapy in Node-Positive ER+/HER2-Breast Cancer Patients-Predictors and Oncologic Outcomes
    Friedman-Eldar, Orli
    Ozmen, Tolga
    El Haddi, Salah James
    Goel, Neha
    Tjendra, Youley
    Kesmodel, Susan B.
    Moller, Mecker G.
    Franceschi, Dido
    Layton, Christina
    Avisar, Eli
    ANNALS OF SURGICAL ONCOLOGY, 2022, 29 (07) : 4102 - 4102
  • [30] Subcellular MLH1 protein as first in class biomarker for CDK4/6 response in endocrine resistant ER+/HER2-breast cancer
    Mazumder, Aloran
    Oropeza, Elena
    Punturi, Nindo
    Haricharan, Svasti
    CANCER RESEARCH, 2024, 84 (06)
12345